MedTrace Logo

Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

NCT06819449 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-02-11

No results posted yet for this study

Summary

Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.

Conditions

  • Leprosy
  • Mycobacterium Leprae Infection

Interventions

DRUG

Dapsone

To evaluate the effect of the multi drug therapy in leprotic patients and their side effects and to assess the role of Rab 32 gene in leprosy prognosis and to know its association with the multi drug therapy.

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • Eisa Mohammed Hegazy, Assist. Prof · Dermatology, Venereology and Andrology. Faculty of Medicine,South Valley University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-20
Primary Completion
2025-12-10
Completion
2025-12-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06819449 on ClinicalTrials.gov